Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability (P5-4.003)

Victor Diego Armengol; Basil T. Darras; Ahmad Abulaban; Ali Mohammed Alshehri; Nina Barišić; Tawfeg Ben‐Omran; Günther Bernert; Claudia Castiglioni; Yin‐Hsiu Chien; Michelle A. Farrar; Gwendoline Kandawasvika; Satish V. Khadilkar; Jean K. Mah; C. Marini-Bettolo; Damjan Osredkar; Gerald Pfeffer; Flávia Piazzon; Inmaculada Pitarch Castellano; Susana Quijano‐Roy; Kayoko Saito; Jin‐Hong Shin; Juan F. Vázquez‐Costa; Maggie C. Walter; Jithangi Wanigasinghe; Hui Xiong; Robert C. Griggs; Bhaskar Roy

doi:10.1212/wnl.0000000000206000

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The primary objective of this study was to compare the availability and implementation of disease-modifying treatment for spinal muscular atrophy (SMA) from different regions of the world.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Armengol et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677f5d https://doi.org/10.1212/wnl.0000000000206000

View at Publisher

Ask AI

Bookmark

Share

Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability (P5-4.003)

Ask about this paper

Abstract

Discussion

Cite This Study

Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability (P5-4.003)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading